Daily Pivots: (S1) 0.9062; (P) 0.9087; (R1) 0.9105; More…. Intraday bias in USD/CHF stays neutral first, and further rise remains mildly in favor as long as 0.9007 support holds. Above 0.9111 will resume the rebound Read more…
Daily Pivots: (S1) 150.50; (P) 151.10; (R1) 151.54; More… While USD/JPY’s retreat from 151.69 is steep, it’s still holding above 148.79 support. Intraday bias remains neutral and some more range trading could be seen. Further Read more…
Daily Pivots: (S1) 1.2110; (P) 1.2137; (R1) 1.2179; More GBP/USD is still bounded in established range despite today’s rebound, and intraday bias stays neutral. On the upside, firm break of 1.2287 resistance will argue that Read more…
In the wake of BoE’s decision to maintain interest rates unchanged, Sterling exhibited a mixed performance, gaining against Dollar yet faltering when paired with the Euro and commodity-linked currencies. The voting pattern at the BoE Read more…
While the time window to take advantage of booking your holiday travel early has now passed (several travel experts have recommended staying home for Thanksgiving if you have not booked a flight yet and do Read more…
US initial jobless claims rose 5k to 217k in the week ending October 28, above expectation of 210k. Four-week moving average of initial claims rose 2k to 210k. Continuing claims rose 35k to 1818k in Read more…
BoE held its Bank Rate steady at 5.25%, aligning with broad market anticipations. The decision came with a 6-3 split, with Megan Greene, Jonathan Haskel, and Catherine Mann opting for a 25 basis points increase. Read more…
Monetary Policy Summary, November 2023 The Bank of England’s Monetary Policy Committee (MPC) sets monetary policy to meet the 2% inflation target, and in a way that helps to sustain growth and employment. At its Read more…
Peloton PTON shares tumbled in pre-market trading after the connected fitness group forecast weaker-than-expected holiday quarter revenues that continue to test its turnaround plans under CEO Barry McCarthy. Peloton said its adjusted loss for the three months Read more…
Eli Lilly LLY posted better-than-expected third quarter earnings Thursday thanks to the ongoing surge in sales for its Mounjaro anti-obesity drug that offset a slump in revenues for its legacy diabetes treatment Trulicity. Shares in the group Read more…